Nature Reviews Endocrinology, Journal Year: 2020, Volume and Issue: 16(11), P. 642 - 653
Published: Sept. 14, 2020
Language: Английский
Nature Reviews Endocrinology, Journal Year: 2020, Volume and Issue: 16(11), P. 642 - 653
Published: Sept. 14, 2020
Language: Английский
Endocrine Practice, Journal Year: 2016, Volume and Issue: 22, P. 1 - 203
Published: May 24, 2016
Language: Английский
Citations
1393Endocrine Practice, Journal Year: 2017, Volume and Issue: 23, P. 1 - 87
Published: April 1, 2017
Language: Английский
Citations
986Diabetes Care, Journal Year: 2015, Volume and Issue: 38(10), P. 1964 - 1974
Published: Sept. 15, 2015
Insights from prospective, longitudinal studies of individuals at risk for developing type 1 diabetes have demonstrated that the disease is a continuum progresses sequentially variable but predictable rates through distinct identifiable stages prior to onset symptoms. Stage defined as presence β-cell autoimmunity evidenced by two or more islet autoantibodies with normoglycemia and presymptomatic, stage 2 dysglycemia 3 symptomatic disease. Adoption this staging classification provides standardized taxonomy will aid development therapies design clinical trials prevent disease, promote precision medicine, provide framework an optimized benefit/risk ratio impact regulatory approval, reimbursement, adoption interventions in early
Language: Английский
Citations
917Endocrine Practice, Journal Year: 2016, Volume and Issue: 22(1), P. 84 - 113
Published: Jan. 1, 2016
Language: Английский
Citations
692Patient Preference and Adherence, Journal Year: 2016, Volume and Issue: Volume 10, P. 1299 - 1307
Published: July 1, 2016
Poor medication adherence in type 2 diabetes: recognizing the scope of problem and its key contributors William H Polonsky,1,2 Robert R Henry2,3 1Behavioral Diabetes Institute, San Diego, 2University California, 3Center for Metabolic Research, VA Diego Healthcare System, San Diego, CA, USA Abstract: At least 45% patients with diabetes (T2D) fail to achieve adequate glycemic control (HbA1c <7%). One major contributing factors is poor adherence. T2D well documented be very common associated inadequate control; increased morbidity mortality; costs outpatient care, emergency room visits, hospitalization, managing complications diabetes. linked nonpatient (eg, lack integrated care many health systems clinical inertia among professionals), patient demographic young age, low education level, income level), critical beliefs about their medications perceived treatment inefficacy), burden regarding obtaining taking complexity, out-of-pocket costs, hypoglycemia). Specific barriers T2D, especially those that are potentially modifiable, need more clearly identified; strategies target should focus on reducing addressing negative patients. Solutions these problems would require behavioral innovations as new methods modes drug delivery. Keywords: control, HbA1c, hypoglycemia, adherence, psychosocial,
Language: Английский
Citations
603The Lancet Diabetes & Endocrinology, Journal Year: 2018, Volume and Issue: 6(4), P. 275 - 286
Published: Feb. 1, 2018
Language: Английский
Citations
584Endocrine Practice, Journal Year: 2020, Volume and Issue: 26(1), P. 107 - 139
Published: Jan. 1, 2020
Language: Английский
Citations
548Endocrine Practice, Journal Year: 2018, Volume and Issue: 24(1), P. 91 - 121
Published: Jan. 1, 2018
Language: Английский
Citations
491Nature Reviews Gastroenterology & Hepatology, Journal Year: 2016, Volume and Issue: 14(3), P. 160 - 169
Published: Nov. 30, 2016
Language: Английский
Citations
441Endocrine Practice, Journal Year: 2017, Volume and Issue: 23(2), P. 207 - 238
Published: Jan. 17, 2017
Language: Английский
Citations
422